Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3024% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker SASB Quality Scorecard by Year
SASB Quality Scorecard — U.S. FDA Inspections Conducted (inspections)
Stryker SASB Quality Scorecard: 17 in FY2025, up 21.4% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
17
Period ended Dec 31, 2025
Change on a year earlier
+21.4%
14 in FY2024
History
8 years
Since FY2018
Sources
5
Documents cited below
Where the FY2025 figure comes from
Reported in Stryker Comprehensive Reports (2021–2025 Quality Management Metrics, FY2018–FY2025).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SASB Quality Scorecard — U.S. FDA Inspections Conducted (inspections) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17 | +21.4% | 2025 Comprehensive Report (ir|comp_report_2025) ↗ |
| FY2024 | Dec 31, 2024 | 14 | +100.0% | 2025 Comprehensive Report (ir|comp_report_2025) ↗ |
| FY2023 | Dec 31, 2023 | 7 | +40.0% | 2025 Comprehensive Report (ir|comp_report_2025) ↗ |
| FY2022 | Dec 31, 2022 | 5 | +25.0% | 2024 Comprehensive Report (ir|comp_report_2024) ↗ |
| FY2021 | Dec 31, 2021 | 4 | +100.0% | 2023 Comprehensive Report (ir|comp_report_2023) ↗ |
| FY2020 | Dec 31, 2020 | 2 | -66.7% | 2022 Comprehensive Report (ir|comp_report_2022) ↗ |
| FY2019 | Dec 31, 2019 | 6 | -53.8% | 2022 Comprehensive Report (ir|comp_report_2022) ↗ |
| FY2018 | Dec 31, 2018 | 13 | – | 2021 Comprehensive Report (ir|comp_report_2021) ↗ |
Breakdown
What makes up SASB Quality Scorecard
- Average Form 483 Observations per FDA Inspection (observations)0.20 · FY2025
- External Regulatory & Notified-Body Quality Audits Worldwide (audits)224 · FY2025
- Average Findings per External Regulatory Audit (findings)0.50 · FY2025
- Internal Corporate Quality Audits Conducted (audits)30 · FY2025
- FDA Class I Recalls Reported (recalls)1 · FY2025
- FDA Class II Recalls Reported (recalls)26 · FY2025
- FDA Class III Recalls Reported (recalls)0 · FY2025
- FDA Recalls Pending Classification at Year-End (recalls)0 · FY2025
- FDA Recalls Normalized per $1B Revenue (recalls / $1B)1.10 · FY2025
- FDA Warning Letters Received (letters)0 · FY2025
- FDA Warning Letters Resolved (letters)0 · FY2025
Cite this data
StockData. (2026). Stryker SASB Quality Scorecard, annual FY2018–FY2025 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/qual-fda-insp
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.